Lilly’s Donanemab Delay: Labeling, Real-World Operationalization May Be Reason For Adcomm

 
• By Sarah Karlin-Smith
document with "delayed" stamped on it
Lilly's donanemab approval for Alzheimer's is delayed due to last minute advisory committee • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers